Seikagaku Corporation

Children's Medical Center Corporation

University of Iowa Research Foundation

Yuyu International Co., Ltd.

Yeong Shik Kim

Koji Yamamoto

Kiyoshi Suzuki

Takeshi Ishimaru

Robert J Linhardt

Hideo Mochizuki

Merton Bernfield

Yong Oh Lee

Kyung Hee Lee

Sung An Kang

Kiwamu Yamagishi

Hye Sook Yun-Choi

Hyung Soo Ann

To provide a polypeptide having heparosan-glucuronate 5-epimerase activity, whereby means for producing a polysaccharide in which hexuronic acid residues has been epimerized is provided. Through screening ofcDNA library, a DNA encoding a polypeptide of heparosan-glucuronate 5-epimerase is obtained. The epimerase acts on glucuronic acid residues of N-acetyl heparosan and/or iduronic acid residues of completely desulfated N-acetylated heparin. The polypeptide encoded by the DNA is expressed by insect cells, to thereby yield the polypeptide having heparosan-glucuronate 5-epimerase activity. By bringing the polypeptide into contact with N-acetyl heparosan or completely desulfated N-acetylated heparin, a polysaccharide in which hexuronic acid residues has been epimerized is yielded.

Heparosan-glucuronic acid-5-epimerase, and method for producing polysaccharide using same

An antibody that reacts with 2-O-desulfated acharan sulfate, a hybridoma that produces the antibody, a detection method and a detection kit to which the antibody is applied are disclosed. The antibody that reacts with 2-O-desulfated acharan sulfate can be produced by immunizing a mammal using as an antigen a substance obtained by chemically bonding a protein to 2-O-desulfated acharan sulfate.

Anti-2-O-desulfated acharan sulfate antibody and its application

An anti-acharan sulfate antibody, a hybridoma that produces the antibody, a detection method and a detection kit to which the antibody is applied are disclosed. The anti-acharan sulfate antibody can be produced by immunizing a mammal using as an antigen a substance obtained by chemically bonding a protein to acharan sulfate.

Anti-acharan sulfate antibody and its application

The invention herein relates to a pharmaceutical composition comprising ticlopidine and Ginkgo biloba extract. In detail, as an anti-thrombotic preparation, the pharmaceutical composition comprising said ticlopidine and Ginkgo biloba extract with the PAF-antagonistic and anti-oxidant actions is used in combination to naturally suppress the neutropenia and agranulocytosis caused by the toxicity resulting from the repeated use of ticlopidine alone.

Pharmaceutical composition comprising ticlopidine and Ginkgo biloba extract

The present invention is based on the unexpected discovery that a molecule having as its major repeating units N-acetylglucosamine alternating in sequence with 2-O-sulfated uronic acid, inhibits FGF mitogenicity, and thus is useful in inhibiting angiogenesis. Additionally, the molecule has low toxicity and inhibits FGF mitogenicity without affecting anticoagulant activity. One preferred molecule is a glycosaminoglycan such as archaran sulfate. The molecules are in pharmaceutical compositions that can be used in the treatment of diseases which are angiogenesis-dependent.

Angiogenesis inhibitors and use thereof

Growing community of inventors

Seoul, South Korea

Yeong Shik Kim